- Saudi Arabia to Double Total Refining Capacity by 2015
- Obama to Outline Strategy to Boost US Exports to Asia
- Friday May See 'Risk Trade' Stalling; Dollar in Focus
- Job Market Politics to Keep Interest Rates Low
- AIG, Symbol of Crisis, Watches Its Stock Zoom Back
- Cities With the Most Home Price Reductions
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Bill Gates Praises Apple's Jobs for 'Saving the Company'
- Is Euphoric Market Ignoring Warning Signs?
- EXCERPTS and IMAGES: Warren Buffett & Bill Gates - Keeping America Great
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Gold Is a Bad Inflation Hedge—Like Oil: Stock Picker
- Intel's Andy Bryant Offers An Explanation
- US 'Actively Working' on Weaker Dollar: Fund Manager
- Options Boil on Biotech Buyout Rumors
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Activision Blizzard's "Modern Warfare 2" Sales Break Records
- 5-Star Manager's 5 Stocks for Changing Markets
MOST SHARED
- CNBC TRANSCRIPT: Warren Buffett & Bill Gates - Keeping America Great
- Pharma & Social Media
- Is Euphoric Market Ignoring Warning Signs?
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- China Fourth Quarter Growth Could Hit 10%: Official
- Obama to Outline Strategy to Boost US Exports to Asia
- Warren Buffett and Bill Gates Share Their 'Optimism' With Eager Columbia Business Students
- Video Game Sales Plunge, but Have They Hit Bottom?
- Bain Finalizing $1.1 Billion Deal to Buy Citi's Bellsystem
Text Size 
Amgen [AMGN
Loading...
()
] said that its anemia drug Aranesp showed no difference in the risk of death compared with a placebo in a closely watched study of the medicine in small-cell lung cancer patients, sending its shares as much as 7%.
Aranesp and similar anemia drugs have been under fire amid concerns that they have been used too aggressively and could be harming patients.
Industry analysts have called results of this study critical to future use of Amgen's most important product. Aranesp had sales of about $4.1 billion last year, and along with its predecessor Epogen accounted for roughly half of Amgen's sales.
Had study 145 -- the first involving this class of drugs to specifically have survival as a primary goal -- shown that Aranesp increased the risk of death in cancer patients undergoing chemotherapy, it would likely have wiped out the lion's share of Aranesp sales. Chemotherapy-induced anemia is by far the most important indication for Aranesp.
"These results contribute to the growing body of evidence on (Aranesp) safety, reinforcing the neutral impact on survival in cancer patients suffering from chemotherapy-induced anemia," Amgen's research and development chief Roger Perlmutter said in a statement.
Aranesp, Epogen and Johnson & Johnson's Procrit are all forms of the natural protein erythropoietin, or Epo, used to treat anemia by stimulating the body's production of hemoglobin, the protein in red blood cells that carries oxygen.
The U.S. Food and Drug Administration last month slapped a strong new warning on the anemia drugs, calling on doctors to use the lowest dose that can effectively avoid the need for blood transfusions.
Amgen, the world's largest biotechnology company, said patients who received Aranesp in study 145 had a significantly lower risk of blood transfusions as the drug significantly boosted hemoglobin levels.
Following a wave of concerning news on the anemia drugs, including increased death seen in an Aranesp study of cancer patients who were not on chemotherapy, Wall Street had been bracing for moderately negative findings from study 145.
Print
Email
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- They may have wrecked their companies or saved our economy. Tell us what you think.
- Big pharma embraces social media, but how much should a tightly regulated sector say on Facebook or Twitter?
- A European dating site finds lovelorn singles from one country to be consistently uglier. Which is it?
- Contributor David Pogue looks at two of the latest efforts to perfect the digital pocket camera.
- PepsiCo is ramping up its onsite health facilities for workers.
Data is a real-time snapshot *Data is delayed at least 15 minutes